Your browser doesn't support javascript.
loading
Critical Role of Tripartite Fusion and LBD Truncation in Certain RARA- and all RARG-Related Atypical APL.
Zhou, Xiaosu; Chen, Xue; Chen, Jiaqi; Wen, Lijun; Zhang, Zhanglin; Qin, Ya-Zhen; Cao, Panxiang; Xing, Haizhou; Mi, Yingchang; Wang, Wei; Zhang, Guangsen Sen; Li, Ji; Wu, Huanling; Zhang, Zhifen; Zhang, Jian; Su, Zhan; Wang, Fang; Zhang, Yang; Ma, Xiaoli; Fang, Jiancheng; Wu, Ping; Wang, Tong; Fan, Gaowei; Zhao, Yang; Jin, David; Zhang, Xian; Ma, Xiujuan; Wu, Qisheng; Zhang, Zhihua; Wang, Linya; Ma, Futian; Xiao, Xia; Wu, Chengye; Sun, Kai; Tang, Ruijie; Zhang, Yun; Wu, Sanyun; Gao, Ran; Zhang, Leping; Zheng, Huyong; Zhao, Yanli; Zhu, Hong-Hu; Lu, Daopei; Lu, Peihua; Chen, Suning; Liu, Hongxing.
Afiliação
  • Zhou X; Beijing Lu Daopei Institute of Hematology, Beijing, China.
  • Chen X; Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Chen J; Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Wen L; National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, China.
  • Zhang Z; The First Affiliated Hospital of Nanchang University, China.
  • Qin YZ; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, China.
  • Cao P; Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Xing H; Department of Hematology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Mi Y; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China.
  • Wang W; Department of Hematology, the Second Clinical College of Harbin Medical University, Harbin, China.
  • Zhang GS; The Second Xiangya Hospital, Central South University, changsha, China.
  • Li J; Department of Hematology, the Second Xiangya Hospital, Central South University, Changsha, China.
  • Wu H; Shandong Provincial Hospital Affliated to Shandong First Medical University, JINAN, China.
  • Zhang Z; Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
  • Zhang J; Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
  • Su Z; The Affiliated Hospital of Qingdao University, QingDao, China.
  • Wang F; Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Zhang Y; Hebei Yanda Ludaopei Hospital, Langfang, China.
  • Ma X; Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Fang J; Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Wu P; Hebei Yanda Lu Daopei Hospital.
  • Wang T; Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Fan G; Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
  • Zhao Y; Peking University People's Hospital, Beijing, Wyoming, China.
  • Jin D; Beijing Lu Daopei Institute of Hematology, Beijing, China.
  • Zhang X; Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Ma X; Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Wu Q; Beijing Lu Daopei Hospital, China.
  • Zhang Z; Department of Hematology, the Afliated Hospital of Chengde Medical College, Chengde, Hebei, China, Chengde Hebei, China.
  • Wang L; Beijing Children's Hospital, Beijing, China.
  • Ma F; Hebei Children's Hospital, Shijiazhuang, Alabama, China.
  • Xiao X; Tianjin First Central Hospital, Tianjin, Alabama, China.
  • Wu C; Institute of Hematology, Zhengzhou University People's Hospital and Henan Provincial People's Hospital, Zhengzhou, China.
  • Sun K; Zhengzhou University People's Hospital and Henan Provincial People's Hospital, Zhengzhou, China.
  • Tang R; Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Zhang Y; The District People's Hospital of Zhangqiu, Jinan, China.
  • Wu S; Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Gao R; The First Hospital of China Medical University, Shenyang, China.
  • Zhang L; Peking University People's Hospital, Beijing, Wyoming, China.
  • Zheng H; Beijing Children's Hospital, Capital Medical University, Beijing, China.
  • Zhao Y; Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Zhu HH; Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
  • Lu D; Beijing Lu Daopei Institute of Hematology, Beijing, China.
  • Lu P; Hebei Yanda Lu Daopei Hospital, Langfang, China.
  • Chen S; National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, China.
  • Liu H; Hebei Yanda Lu Daopei Hospital, Langfang, China.
Blood ; 2024 Jul 24.
Article em En | MEDLINE | ID: mdl-39046762
ABSTRACT
Atypical acute promyelocytic leukemia (aAPL) presents a complex landscape of retinoic acid receptor (RAR) fusion genes beyond the well-known PMLRARA fusion. Among these, 31 individually rare RARA and RARG fusion genes have been documented, often reported in the canonical XRAR bipartite fusion form. Intriguingly, some artificially mimicked bipartite XRAR fusions respond well to all-trans retinoic acid (ATRA) in vitro, contrasting with the ATRA resistance observed in patients. To unravel the underlying mechanisms, we conducted a comprehensive molecular investigation into the fusion transcripts in 27 RARA fusion gene-positive aAPL (RARA-aAPL) and 21 RARG-aAPL cases. Our analysis revealed an unexpected novel form of XRARX or XRARY-type tripartite fusions in certain RARA- and all RARG-aAPL cases, with shared features and notable differences between these two disease subgroups. In RARA-aAPL cases, the occurrence of RARA 3' splices was associated with their 5' fusion partner genes, mapping across the coding region of helix 11_12 (H11_12) within the ligand-binding domain (LBD), resulting in LBD-H12 or H11_12 truncation. In RARG-aAPL cases, RARG 3' splices were consistently localized to the terminus of exon 9, leading to LBD-H11_12 truncation. Significant differences were also observed between RARA and RARG 5' splice patterns. Our analysis also revealed extensive involvement of transposable elements in constructing RARA and RARG 3' fusions, suggesting transposition mechanisms for fusion gene ontogeny. Both protein structural analysis and experimental results highlighted the pivotal role of LBD-H11_12/H12 truncation in driving ATRA unresponsiveness and leukemogenesis in tripartite fusion-positive aAPL, through a protein allosteric dysfunction mechanism.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article